$60M B round to propel Landos through Phase II IBD trials

$60M B round to propel Landos through Phase II IBD trials

Source: 
BioCentury
snippet: 

Landos' $60 million series B will enable it to complete two Phase II trials, one each in ulcerative colitis and Crohn's disease, of lead product BT-11.